Skip to main content
Premium Trial:

Request an Annual Quote

Chemicon Sublicenses RNAi Technology from Promega

NEW YORK, Feb. 17 (GenomeWeb News) - Chemicon International has sub-licensed an RNAi technology from Promega, the companies said today.

 

Under the agreement, Temecula, Calif.-based Chemicon, a research division of Serologicals, has the right to develop and sell products for DNA-directed RNA interference for life science research. Promega will also help Chemicon develop ddRNAi products for studying mammalian genes.

 

Madison, Wis.-based Promega holds an exclusive license for ddRNAi technology from Benitec of Queensland, Australia.

 

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.